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OBJECTIVES: Erythropoietin may have neuroprotective potential after ischemia of the central nervous system.
Here, we conducted a study to characterize the protective effects of erythropoietin on retinal ganglion cells and
gliotic reactions in an experimentally induced oligemia model.
METHODS: Rats were subjected to global oligemia by bilateral common carotid artery occlusion and then
received either vehicle or erythropoietin via intravitreal injection after 48 h; they were euthanized one week after
the injection. The densities of retinal ganglion cells and contents of glial fibrillary acidic protein (astrocytes/Mu¨ller
cells) and cluster of differentiation 68 clone ED1 (microglia/macrophages), assessed by fluorescence intensity, were
evaluated in frozen retinal sections by immunofluorescence and epifluorescence microscopy.
RESULTS: Retinal ganglion cells were nearly undetectable one week after oligemia compared with the sham
controls; however, these cells were partially preserved in erythropoietin-treated retinas. The contents of glial
fibrillary acidic protein and cluster of differentiation 68 clone ED1, markers for reactive gliosis, were significantly
higher in retinas after bilateral common carotid artery occlusion than those in both sham and erythropoietin-
treated retinas.
CONCLUSIONS: The number of partially preserved retinal ganglion cells in the erythropoietin-treated group
suggests that erythropoietin exerts a neuroprotective effect on oligemic/ischemic retinas. This effect could be
related to the down-modulation of glial reactivity, usually observed in hypoxic conditions, clinically observed
during glaucoma or retinal artery occlusion conditions. Therefore, glial reactivity may enhance neurodegenera-
tion in hypoxic conditions, like normal-tension glaucoma and retinal ischemia, and erythropoietin is thus a
candidate to be clinically applied after the detection of decreased retinal blood flow.
KEYWORDS: Hematopoietic Growth Factor; Retinal Ganglion Cells; Glial Cells; Neuroprotection; Bilateral
Common Carotid Artery Occlusion.
’ INTRODUCTION
Erythropoietin (EPO) is a glycoprotein secreted in response
to hypoxia that stimulates the differentiation and prolifera-
tion of erythrocyte progenitor cells and may have additional
physiological effects as a cytokine with antiapoptotic, neuro-
trophic, angiogenic and antioxidant roles (1-4). The neuro-
protective potential of EPO has been described in several
animal models of central nervous system (CNS) injury.
In murine models of focal cerebral ischemia induced by
permanent occlusion of the middle cerebral artery, the
chronic intraventricular administration of EPO 24 hours
before the ischemic injury reduced the size of the brain lesion
area compared to that in animals that received no pre-
conditioning (1). In brain damage by freezing, intraperitoneal
EPO administration reduced behavioral disorders, cognitive
dysfunction, and brain atrophy for more than eight months
after injury (5). Systemic EPO administration after the devel-
opment of spinal cord lesions decreased the rate of apoptosis
in dorsal root ganglion cells (6). However, the exact mecha-
nisms underlying these neuroprotective effects are not yet
fully elucidated.
Because the retina may also be affected by degenerative
events like those in other parts of the CNS and considering
the neuroprotective potential of EPO as a treatment for
pathological retinal conditions (7-9), interest in investigating
the effects of exogenous EPO administration in various
animal models of retinal degeneration has grown. Herein, weDOI: 10.6061/clinics/2018/e161
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report for the first time an evaluation of the neuroprotective
potential of EPO after the induction of retinal ischemia in rats
using the bilateral common carotid artery occlusion (BCCAO)
technique, which mimics human retinopathy caused by the
occlusion of this artery or its branches (10).
’ MATERIALS AND METHODS
1. Oligemia model
Protocols for animal use were approved by the Ethics
Committee for Use of Experimental Animals at the Federal
University of Rio de Janeiro (UFRJ, process IBCCF020).
Twenty young-adult male Wistar rats (aged 3 months) were
anesthetized with a mixture of ketamine (70 mg/kg) and
xylazine (8 mg/kg, intraperitoneal). After making a cervical
medial and ventral incision, the common carotid artery was
bilaterally exposed and tied at two levels 2 mm apart from
each other. The arteries were sectioned between the two ties.
Sham animals (n=5) underwent artery exposure but were
not subjected to artery tying and sectioning. During anesthesia,
the body temperatures of the rats was maintained at 37-38oC
with a heated blanket.
2. EPO treatment
After surgery, all rats were housed in individual cages
with easy access to food and water and received tramadol
(200 mg/kg, subcutaneous) and enrofloxacin (7.5 mg/kg,
subcutaneous). Two days later, a group of 10 rats received
either an intravitreal injection of either 1 ml of phosphate
buffered saline (PBS) or 1 ml of EPO (400 mg diluted in PBS).
Five additional rats were only subjected to BCCAO as a
control and received no intravitreal injection.
3. Histology, immunofluorescence, cell counting
and quantification of fluorescence intensity
Ten days after surgery, sham and experimental animals
were euthanized with an overdose of pentobarbital. Their
eyes were then removed and opened, and the posterior
portions were fixed with 4% paraformaldehyde in phosphate
buffer (PB). These portions were cryoprotected in PB with
30% sucrose overnight and sectioned (12-mm thickness).
The sections were collected on glass slides pre-coated with
poly-L-Lysine. Next, a portion of the material obtained
was processed for routine histology to observe the general
architecture. Images were acquired with a Carl Zeiss Axioimager
M2 microscope.
For immunofluorescence (11), the following primary anti-
bodies were used: mouse anti-Brn3a (retinal ganglion cells,
RGC) (12), 1:100, Millipore, USA), rabbit anti-GFAP (astrocytes/
Müller cells; 1:100, Millipore) and mouse ED1 (microglia/
macrophages, 1:100, Millipore). The secondary antibodies used
were anti-mouse conjugated to Alexa 488 and anti-rabbit
conjugated to Alexa 647 (1:400; Life Technologies, USA).
Every other retinal serial section obtained after cryotomy
was used. Cell bodies in the central retina located approxi-
mately 1 mm from the optic disc labeled with brain-specific
homeobox/POU domain protein 3A (Brn3a), glial fibrillary
acidic protein (GFAP) or cluster of differentiation 68 clone
ED1 (ED1) were counted using a microscope (Carl Zeiss
Axioimager M2) with an EC-Plan Neofluar 40/1.30 Oil DIC
M27 objective.
To quantify the fluorescence emission intensities of the
GFAP and ED1 markers, the originally acquired image data
were used. Mean intensity levels (mean intensity profile,
ImageJ imaging software) were calculated from the central
retinal areas and expressed as pixel gray-scale values. To
compare the overall fluorescence intensities of the retina
tissue samples, mean fluorescence intensities were calculated
from the selected comparable image areas displaying the
central retina as the typical histological structure (sham
retina, Fig. 1A). Images for each experimental condition were
acquired using identical microscopic image settings. The
mean fluorescence emission intensities of the negative con-
trols (with primary antibody suppression) were defined as
the negative control reference value, and the mean fluores-
cence intensities of the sections were set after the treatments.
Statistical analyses were performed using GraphPad Prism
software (version 5.0.0.288). Data are expressed as the mean±
standard error of the mean (SEM) and were analyzed by one-
way ANOVA followed by the Student-Newman-Keuls test.
P values o0.05 were considered significant.
’ RESULTS
Ten days after the rats were subjected to oligemia, retinas
of both the BCCAO and PBS groups showed reduced
thickness compared with that of the sham group, and both
plexiform layers appeared to be disorganized (Figure 1 A-C).
However, treatment with EPO preserved both the retinal
thickness and the organization of the layers. Furthermore,
the number of RGCs in the EPO group was significantly
increased compared to that in the other groups that under-
went BCCAO surgery, although the amount was not similar
to that in the sham group (Figure 1D).
Compared with that in the sham group, Brn3a labeling
revealed a significant loss of RGCs in both the BCCAO and
the PBS groups (Figure 1E-G) and labeling of a considerable
number of cells after EPO administration (Figure 1H). Quan-
tification of Brn3a-positive RGCs showed that 10 days after
surgery, BCCAO retinas contained fewer RGCs than those
of the sham group. Retinas receiving PBS also showed a
substantially reduced number of Brn3a-positive cells com-
pared with that in the sham group. However, retinas treated
with EPO (48 h after surgery) had 57% of their RGCs pre-
served compared to that in BCCAO retinas (Figure 2A).
After retinal trauma, reactive gliosis occurs, as revealed by
the overexpression of GFAP (13,14). Therefore, to determine
whether EPO could serve as an effective modulator of glial
reactivity, we analyzed the fluorescence pattern of GFAP in
the retinas of rats subjected to BCCAO. Retinas of BCCAO
and PBS group rats showed increased GFAP labeling com-
pared with those of sham group rats (Figure 1I-K). However,
retinas treated with EPO showed reduced GFAP labeling
(Figure 1L) compared with that in sham retinas. Quantifica-
tion of fluorescence showed that retinas of the BCCAO and
PBS groups (especially the latter) had either more astrocytes/
Müller cells or were more reactive to the injury (Figure 2B).
Additionally, fluorescence in EPO-treated retinas was decrea-
sed to a larger extent compared with that in the BCCAO and
PBS groups and was increased compared with that in the
sham group (Figure 2B).
Similarly, reactive microglia have been detected in the
retina and optic nerve after injury and shown to contribute
to neuronal death (15-17). Immunofluorescence labeling of
ED1, which is usually upregulated in reactive microglia/
macrophages (18), revealed the presence of many more
cells in both the BCCAO and PBS groups compared
with those in the sham and EPO groups (Figure 1 M-P).
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Finally, quantification of fluorescence labeling showed that
retinas of both the BCCAO and PBS groups had more
microglia/macrophages than the sham and EPO groups.
Although there was a difference in the number of sham and
EPO retinas, it was not as large as the increased fluorescence
intensities in both the BCCAO and PBS groups (Figure 2C).
’ DISCUSSION
In this study, we showed that EPO injection into the
vitreous chamber of oligemia model rats allowed mainte-
nance of about half the number of RGCs and reduced both
the macroglial reactivity and the number of retinal microglia/
macrophages.
In humans, the inner retina is very sensitive to hypoxia or
other insults (19). Because EPO is present in the retina
(19,20), several studies have examined its potential neuro-
protective role in the visual system (21-29). However,
although EPO has been used to treat ocular disorders, con-
cerns as to whether it worsens pathogenicity or provides
protection against eye diseases have been raised. For a
review, see (30).
In this study, the reduction of RGCs after BCCAO
mimicked insults that affect the human eye, such as hypoxia
resulting from glaucoma or retinal ischemia (31,32). Although
astrocytes and Müller cells are known to produce and secrete
neuroprotective factors, and Müller cells are the main source
of EPO in the normal retina (20), our data suggest that RGCs
are rescued by intravitreal EPO injection. We observed a
strong reactivity to GFAP, which may indicate that both
Müller cells and astrocytes respond to BCCAO. Additionally,
the increased number of reactive microglia/macrophages
indicates that a reactive mechanism occurs after BCCAO.
In humans, promising results have been reported using
systemic and intravitreal EPO for different ocular conditions
(33,34; for a review see 35), and understanding its effects is
important for developing better therapies for other patholo-
gical retinal conditions. The BCCAOmodel, used here for the
first time to evaluate the effects of EPO on the retina, is useful
because it creates an experimental condition comparable to
Figure 1 - Representative micrographs of retinal sections. (A-P). (A-D) Hematoxylin and eosin (H&E)-stained retinal sections of control
retinas (sham), (B) retinas subjected to oligemia by bilateral common carotid artery occlusion (BCCAO), (C) retinas subjected to BCCAO
and treated with PBS (PBS), and (D) retinas subjected to BCCAO and treated with erythropoietin (EPO). Note the prominent swelling of
neuronal cell bodies and shrinkage of the inner nuclear layer (INL), inner plexiform layer (IPL) and ganglion cell layer (GCL) in B and C.
(E-H) Retinal sections immunoreacted with Brn3a showing RGC-positive cells (green) under different conditions: (E) Sham, (F) BCCAO
only, (G) BCCAO with PBS treatment, and (H) EPO-treated retinas ten days after oligemia. Brn3a expression is restricted to the GCL and,
although labeling is less evident, more Brn3a-labeled cells are present in EPO retinas (H) than in BCCAO (F) or PBS (G) retinas. (I-P)
Retinal sections immunoreacted with glial markers (GFAP (I-L) and ED1 (M-P), red) under different conditions: (I,M) Sham, (J,N) BCCAO
only, (K,O) PBS, and (L,P) EPO retinas ten days after oligemia. In sham retinas, GFAP-positive cells are more restricted to the GCL, and
ED1-positive cells are barely detectable. In both BCCAO (J,N) and PBS retinas (K,O), GFAP- and ED1-positive cells extend throughout
the entire retinal thickness, while the labeling is less evident in EPO retinas (L,P) than in the previous conditions, indicating decreased
glial reactivity and inflammation ten days after oligemia. Scale bars. 50 mm. Abbreviations: PL, photoreceptor layer; ONL, outer nuclear
layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; and GCL, ganglion cell layer.
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normal tension (36). This model also mimics narrowing of
the internal carotid artery, a common and asymptomatic
condition of systemic arteriosclerosis (37).
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